Physician profile
Mark G Yohe
NPI 1346403995
$1,741.48
in general payments reported to CMS, 2019-2025
51 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $157 · 2021: $358 · 2022: $216 · 2023: $261 · 2024: $149 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $128.06 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $109.04 | 2021-2025 | Nucala, Arexvy, Shingrix |
| Pfizer INC. | $87.23 | 2021-2025 | |
| Lilly USA, LLC | $84.87 | 2019-2024 | Mounjaro |
| Boston Scientific Corporation | $74.48 | 2019-2025 | Intracept, General - Pain Management |
| Abbvie INC. | $73.43 | 2019-2025 | |
| Novo Nordisk INC | $65.00 | 2019-2022 | |
| Antares Pharma, INC. | $61.22 | 2019-2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $59.26 | 2020-2022 | |
| Abbott Laboratories | $47.24 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $41.06 | 2021-2025 | Veozah |
| Nevro Corp. | $40.69 | 2020 | |
| Sanofi-Aventis U.S. LLC | $39.43 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $38.99 | 2021-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.95 | 2019-2023 | Ofev |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yohe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.